Whalesbook: AI-Powered Stock Updates via WhatsApp

Stock Analysis

Description

Alembic Pharmaceuticals Limited is a vertically integrated, research-driven pharmaceutical company based in India, established in 1907. It manufactures and markets generic pharmaceutical products globally and is a leader in branded generics in India, with state-of-the-art R&D and manufacturing facilities approved by major regulatory authorities.

Key Growth Triggers

Receipt of tentative approval from the USFDA for Bosutinib Tablets, 400 mg, targeting a significant market opportunity in the treatment of Chronic Myeloid Leukemia (CML).
The company's ongoing efforts to expand its product portfolio in the regulated US market, evidenced by its cumulative 232 ANDA approvals.

Order Book

Currently no data available for Order Book.

Key Red Flags

Currently no data available for Key Red Flags.

Key Dates To Watch

The company's cumulative USFDA ANDA approvals now stand at 232, with 212 final and 20 tentative approvals, indicating continued regulatory progress.

Corporate Announcements

16th Apr 26

Impact Rating: 8

Alembic Pharmaceuticals Limited has secured final approval from the USFDA for its Methotrexate Injection USP. This approval covers both multi-dose vials (50 mg/2 mL) and single-dose vials (1g/40 mL).

15th Apr 26

Impact Rating: -

No description available.

8th Apr 26

Impact Rating: 3

Alembic Pharmaceuticals submitted a SEBI compliance certificate, issued by its registrar MUFG Intime India Private Limited, confirming securities dematerialisation compliance for the quarter ended March 31, 2026 to the stock exchanges.

7th Apr 26

Impact Rating: 9

Alembic Pharmaceuticals secured USFDA final approval for its Dapagliflozin Tablets, 5 mg and 10 mg. This milestone makes the company eligible for 180 days of shared generic drug exclusivity in the US market.

6th Apr 26

Impact Rating: 6

CRA Family Trust has submitted its annual compliance certificate, issued by D. K. Mehta & Co. Chartered Accountants, to the BSE. This confirms Alembic Pharmaceuticals Limited's adherence to a SEBI Exemption Order for the financial year ended March 31, 2026.

Peer Comparision

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Sun Pharma.Inds.	1782.60	37.05	427717.60	0.90	3124.95	2.56	14478.31	8.93	20.21	54964.01	30.12	11543.96	3117.95	5.50	12.97	0.07
2.	Divi's Lab.	6642.50	70.94	176292.38	0.45	689.00	35.10	2715.00	16.12	20.44	10029.00	32.37	2485.00	689.00	11.44	13.53	0.01
3.	Torrent Pharma.	4092.20	63.93	138496.88	0.78	591.00	32.49	3302.00	14.30	27.05	12248.00	32.60	2166.53	600.17	16.39	13.26	0.33
4.	Cipla	1467.90	21.80	118607.61	0.89	1353.37	3.73	7589.44	7.64	22.72	28349.57	25.40	5441.14	1351.17	3.60	14.72	0.01
5.	Dr Reddy's Labs	1242.80	17.97	103748.51	0.64	1336.80	7.28	8828.30	9.83	22.69	34310.00	24.64	5772.20	1347.10	2.88	12.95	0.16
6.	Lupin	2214.30	23.36	101043.20	0.54	1484.83	73.34	7047.51	24.23	21.30	24750.69	27.25	4324.63	1477.92	5.15	12.41	0.32
7.	Mankind Pharma	2311.80	54.55	95387.58	0.04	520.18	-22.00	3697.16	20.77	15.98	13545.67	24.12	1748.55	511.51	6.24	8.89	0.55
8.	Alembic Pharma	823.70	36.49	16201.70	1.34	179.36	15.63	1796.24	13.66	11.33	6267.14	13.84	444.03	179.36	3.08	7.01	0.27
–	Median: 150 Co.	409.67	31.12	1757.37	0.11	13.03	12.32	157.2	10.84	14.98	582.87	15.96	44.55	13.73	3.15	8.6	0.22

Quarterly Results

Standalone figures in ₹ crores

	Dec 2022	Dec 2023	Dec 2024	Jun 2023	Jun 2024	Jun 2025	Mar 2023	Mar 2024	Mar 2025	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales	1,310	1,588	1,406	1,332	1,476	1,494	1,307	1,475	1,571	1,354	1,479	1,580	1,796
Expenses	1,086	1,251	1,226	1,167	1,184	1,280	1,138	1,186	1,400	1,109	1,271	1,321	1,493
Operating Profit	224	337	180	166	291	214	169	288	171	245	207	259	303
Other Income	1	3	15	12	3	8	2	7	13	0	9	29	11
Profit before tax	144	257	104	98	213	126	84	216	92	167	134	200	216
Tax %	17%	9%	17%	-0%	17%	18%	-55%	7%	18%	12%	-0%	17%	17%
Net Profit	119	233	86	98	176	104	131	202	75	146	134	166	179
EPS in Rs	6.06	11.87	4.37	4.96	8.96	5.27	6.64	10.27	3.83	7.45	6.81	8.43	9.12

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	1,844	2,019	3,009	2,986	2,945	3,660	4,133	5,067	5,035	5,149	5,874	6,033	6,267
Expenses	1,485	1,611	2,026	2,353	2,313	2,782	2,930	3,618	4,127	4,484	4,875	5,131	5,400
Operating Profit	359	408	983	633	633	879	1,203	1,449	909	665	999	901	868
Other Income	4	3	7	3	7	6	125	84	51	3	31	61	48
Interest	10	3	4	3	2	15	25	13	17	49	54	76	91
Depreciation	40	44	72	83	102	106	136	183	285	273	271	277	287
Profit before tax	312	363	914	550	535	765	1,167	1,338	658	346	704	609	537
Net Profit	238	287	699	431	422	611	969	1,097	544	347	666	503	444
EPS in Rs	12.64	15.20	37.06	22.84	22.38	32.42	51.42	55.79	27.65	17.64	33.91	25.60	22.59
Dividend Payout %	24%	23%	11%	18%	18%	17%	19%	25%	36%	45%	32%	43%	–

Balance Sheet

Standalone figures in ₹ crores

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	38	38	38	38	38	38	38	39	39	39	39	39	39
Reserves	592	796	1,493	1,830	2,157	2,675	3,308	5,062	5,251	4,375	4,870	5,155	5,216
Borrowings	109	194	-0	8	622	1,059	1,687	584	706	710	492	1,194	1,393
Other Liabilities	423	484	651	634	862	777	846	958	1,078	1,006	998	1,168	1,212
Total Liabilities	1,162	1,511	2,182	2,509	3,678	4,549	5,879	6,643	7,074	6,130	6,399	7,556	7,860
Fixed Assets	397	489	697	799	918	1,085	1,276	1,774	1,771	2,377	2,536	2,513	2,592
Gross Block	665.06	802.85	1,082.44	948.64	1,162.61	1,435.06	1,761.67	2,452.31	2,733.10	3,441.27	3,859.15	4,100.64	–
Accumulated Depreciation	268.10	314.17	385.19	149.63	244.31	349.62	485.21	678.49	962.00	1,063.82	1,323.49	1,587.17	–
CWIP	21	83	92	348	741	1,107	1,570	2,183	2,304	601	524	837	903
Investments	33	33	37	103	299	506	833	343	219	229	227	260	261
Other Assets	711	906	1,355	1,259	1,720	1,850	2,199	2,344	2,779	2,922	3,112	3,946	4,105
Total Assets	1,162	1,511	2,182	2,509	3,678	4,549	5,879	6,643	7,074	6,130	6,399	7,556	7,860

Cash Flows

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	263	180	848	327	305	809	540	1,485	545	730	773	227
Cash from Investing Activity	-111	-199	-292	-511	-794	-754	-822	-926	-369	-461	-329	-636
Cash from Financing Activity	-151	18	-276	-96	498	80	166	-534	-217	-261	-445	404
Net Cash Flow	1	-1	280	-280	9	135	-116	25	-40	8	-2	-6

Ratios

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	52	61	45	57	77	54	69	30	72	85	83	90
Inventory Days	159	195	240	237	274	325	375	376	339	280	274	403
Days Payable	144	162	225	177	246	173	137	148	139	131	126	148
Cash Conversion Cycle	66	95	60	117	105	207	307	258	272	234	232	345
Working Capital Days	45	42	57	82	94	44	58	80	83	85	102	94
ROCE %	47%	41%	72%	32%	23%	24%	27%	25%	12%	7%	14%	11%

Shareholding Pattern

Numbers in percentages

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.67%	69.68%	69.74%
FIIs	4.99%	4.55%	4.34%	4.51%	4.52%	4.46%	4.32%	3.94%	4.17%	3.94%	3.96%	4.04%
DIIs	12.76%	13.32%	13.65%	14.22%	14.51%	15.39%	15.47%	16.05%	16.05%	16.43%	16.46%	16.30%
Public	12.64%	12.53%	12.39%	11.67%	11.36%	10.54%	10.61%	10.38%	10.17%	9.96%	9.91%	9.92%